Form 4: GT Biopharma CFO Alan Urban Acquires Options to Purchase Common Stock
SEC Form 4
Alan Urban, CFO of GT Biopharma, acquired options to purchase 23,335 shares of common stock on October 17, 2024.
Summary
- On October 17, 2024, Alan Urban, the Chief Financial Officer of GT Biopharma, Inc., acquired options to purchase 23,335 shares of the company's common stock.
- The exercise price of these options is $2.11 per share.
- The options vest monthly, with 1/36th of the shares vesting on each monthly anniversary of June 3, 2024, until fully vested.
- Full acceleration of vesting occurs if Mr. Urban is involuntarily terminated without cause, resigns for good reason, or in the event of a change in control.
- The options expire on October 16, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction related to executive compensation. The acquisition of options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
Positives
- The acquisition of options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This type of transaction is common for executive compensation packages in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Option grants are a standard component of executive compensation in the biotech industry.
- Comparing the size of this option grant to similar companies and executive roles would require further analysis of GT Biopharma's compensation strategy and peer group data.
- Companies like Amgen, Gilead, and Biogen often use stock options as part of their executive compensation packages.
Stakeholder Impact
- The granting of options to the CFO aligns his interests with those of shareholders, potentially incentivizing him to improve company performance.
Key Dates
| Date | Description |
|---|---|
| June 3, 2024 | Date from which the options begin to vest monthly. |
| June 7, 2024 | Date of the reporting person's Employment Agreement. |
| October 17, 2024 | Date of the transaction where Alan Urban acquired the options. |
| October 16, 2034 | Expiration date of the options. |
Keywords
GT Biopharma, Alan Urban, CFO, options, common stock, acquisition, vesting, insider trading, GTBP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.